Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DehydraTECH-THC is a **proprietary oral tetrahydrocannabinol formulation and delivery technology** developed by Lexaria Bioscience that combines THC with a lipid-based DehydraTECH \"Coat-and-Bond\" processing approach to improve gastrointestinal absorption and systemic delivery. The formulation is designed to reduce first-pass hepatic metabolism, accelerate onset, increase bioavailability, and mask undesirable taste and odor relative to conventional oral THC products. It has been positioned primarily for cannabis edibles, beverages, and other oral cannabinoid products in recreational and medical cannabis settings rather than as a standalone disease-specific prescription therapeutic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DehydraTECH-THC.